MindMed Announces Chief Executive Officer Transition
News provided by
Share this article
Share this article
NEW YORK, June 9, 2021 /PRNewswire/ Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the Company ), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Company s co-founder and chief executive officer, is stepping down as chief executive officer and a director, and that its chief development officer, Robert Barrow, will assume the position of chief executive officer with immediate effect. The Company will also initiate a comprehensive search for a chief executive officer, in which Mr. Barrow will be a candidate, and Mr. Rahn will advise the Company during its leadership transition. The transition of the Company s leadership team will enable the Company to pursue aggressively its clinical development programs and development of its companion innovative digital techno
/PRNewswire/ RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that Mr. Adi Frish,.
/PRNewswire/ With a brand-new location in Ladera Ranch, EoS Fitness makes kicking off summer fitness plans as easy as checking into the gym. Members are.
Share this article
Share this article
LOWELL, Mass., June 9, 2021 /PRNewswire/ Alcyone Therapeutics ( Alcyone ), a biotechnology company pioneering next-generation precision central nervous system (CNS) therapies to improve the lives of patients and families impacted by severe neurological conditions, today announced its launch and $23 million in funding from funds affiliated with RTW Investments, LP ( RTW ). Piratip Pratumsuwan, Managing Director at RTW, will join Alcyone s Board of Directors.
Alcyone s optioned pipeline currently includes 12 adeno-associated virus (AAV) gene therapy programs for severe CNS disorders. Alcyone s four gene therapy platform technologies include X-reactivation, conventional transgene replacement, vectorized exon skipping and promotor modulation.
Through a collaboration, Alcyone s proprietary, next-generation CNS delivery platform and product development, manufacturing and commercialization capabilities will unite with four gene therapy technologi
/PRNewswire/ Sulphobutyl ether β-cyclodextrin (SBE-β-CD) is used as an excipient to improve the solubility and stability of a range of active pharmaceutical.